Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5220467
Max Phase: Preclinical
Molecular Formula: C70H107IN22O20S4
Molecular Weight: 1831.93
Associated Items:
ID: ALA5220467
Max Phase: Preclinical
Molecular Formula: C70H107IN22O20S4
Molecular Weight: 1831.93
Associated Items:
Canonical SMILES: C[C@@H](O)[C@@H]1NC(=O)[C@H]2NC(=O)[C@H](NC(=O)CN)CSSC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)O)NC1=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)c(I)c1)C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(=O)N[C@H](CC(=O)N[C@@H](CCCN)C(=O)O)Cc1ccc(O)cc1)CSSC2(C)C
Standard InChI: InChI=1S/C70H107IN22O20S4/c1-34(94)54-64(109)88-45(29-53(99)100)66(111)93-24-8-13-49(93)63(108)86-42(12-7-23-80-69(77)78)58(103)89-47-32-115-114-31-46(83-52(98)30-74)62(107)92-55(65(110)91-54)70(2,3)117-116-33-48(60(105)81-37(25-35-14-17-38(95)18-15-35)28-51(97)82-43(67(112)113)10-5-21-73)90-57(102)40(9-4-20-72)84-59(104)44(27-36-16-19-50(96)39(71)26-36)87-56(101)41(85-61(47)106)11-6-22-79-68(75)76/h14-19,26,34,37,40-49,54-55,94-96H,4-13,20-25,27-33,72-74H2,1-3H3,(H,81,105)(H,82,97)(H,83,98)(H,84,104)(H,85,106)(H,86,108)(H,87,101)(H,88,109)(H,89,103)(H,90,102)(H,91,110)(H,92,107)(H,99,100)(H,112,113)(H4,75,76,79)(H4,77,78,80)/t34-,37+,40+,41+,42+,43+,44+,45+,46-,47+,48+,49+,54+,55-/m1/s1
Standard InChI Key: QHPSFIKTRMNNLZ-TZHKBYJCSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1831.93 | Molecular Weight (Monoisotopic): 1830.5960 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Gajewiak J, Christensen SB, Dowell C, Hararah F, Fisher F, Huynh PN, Olivera BM, McIntosh JM.. (2021) Selective Penicillamine Substitution Enables Development of a Potent Analgesic Peptide that Acts through a Non-Opioid-Based Mechanism., 64 (13.0): [PMID:34142837] [10.1021/acs.jmedchem.1c00512] |
Source(1):